Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa.

Avigdor Nosrati,McCall E Torpey, Neda Shokrian,Peter Y Ch'en,Tyler M Andriano,Gabrielle Benesh, Haley D Heibel,H Dean Hosgood,Kristina L Campton,Steven R Cohen

International journal of dermatology（2022）

引用 2|浏览7

暂无评分

摘要

We identified significantly lower efficacy of adalimumab in HS patients with BMI ≥ 30 compared to those with BMI < 30. Those with BMI ≥ 30 demonstrated signs of both clinical and physiological deterioration while on adalimumab. Future studies are needed to examine adalimumab dosing for HS patients with high BMI, as well as a critical reconsideration of weight-based therapies.

查看译文

关键词

hidradenitis suppurativa,body mass index,body mass,<scp>bmi</scp>

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要